Dialysis Hyperphosphatemia Therapeutics Market Report 2026

Dialysis Hyperphosphatemia Therapeutics Market Overview

• Dialysis Hyperphosphatemia Therapeutics market size has reached to $4.47 billion in 2025 • Expected to grow to $7.34 billion in 2030 at a compound annual growth rate (CAGR) of 10.3% • Growth Driver: The Increasing Prevalence Of Chronic Kidney Disease Driving The Growth Of The Market Due To Rising Incidence Of Diabetes • Market Trend: First-In-Class Phosphate Absorption Inhibitors Enhance Serum Phosphorus Control And Reduce Pill Burden • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Dialysis Hyperphosphatemia Therapeutics Market?

Dialysis hyperphosphatemia therapeutics refers to the treatments and medications used to manage elevated phosphate levels in patients undergoing dialysis due to chronic kidney disease or kidney failure. These therapeutics help reduce phosphate accumulation in the blood, prevent complications such as bone disorders and cardiovascular disease, and improve overall patient health outcomes. The main types of dialysis hyperphosphatemia therapeutics include phosphate binder drugs, novel first in class mechanisms, and combination therapies. Phosphate binder drugs refer to medications that bind dietary phosphate in the gastrointestinal tract to reduce phosphate absorption and help control elevated phosphate levels in patients undergoing dialysis. These therapeutics are used in hemodialysis, peritoneal dialysis, home hemodialysis, and nocturnal dialysis and are available as tablets or capsules, powder or granules, and other dosage forms. The various applications involved are end stage renal disease, chronic kidney disease stage, and post transplant care and they are utilized by end users including dialysis centers, hospitals and nephrology clinics, home dialysis patients, and long term care facilities.

What Is The Dialysis Hyperphosphatemia Therapeutics Market Growth Forecast?

The dialysis hyperphosphatemia therapeutics market size is expected to see rapid growth in the next few years. It will grow to $7.34 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%.The growth in the forecast period can be attributed to growing development of novel first in class phosphate control therapies, rising demand for personalized renal disease management, increasing focus on combination therapy approaches, growing adoption of home dialysis treatment models, expanding investment in advanced kidney disease research. Major trends in the forecast period include increasing development of advanced phosphate binder therapies, growing adoption of personalized hyperphosphatemia treatment approaches, rising focus on improved patient compliance with oral therapeutics, increasing research on novel mechanisms for phosphate control, growing demand for safer and more effective dialysis support therapies.

What Is The Driver Of The Dialysis Hyperphosphatemia Therapeutics Market?

The increasing prevalence of chronic kidney disease is expected to propel the growth of the dialysis hyperphosphatemia therapeutics market going forward. Kidney disease refers to a group of conditions in which the kidneys are damaged or unable to effectively filter waste, excess fluids, and toxins from the blood, leading to impaired body function and potential health complications. The increasing prevalence of chronic kidney disease is due to the rising incidence of diabetes, which can damage the kidneys over time by affecting their ability to filter waste and excess fluids from the blood. Dialysis hyperphosphatemia therapeutics contributes to kidney disease management by controlling elevated phosphate levels in patients undergoing dialysis, thereby reducing complications such as bone disorders, cardiovascular damage, and mineral imbalance. For instance, in June 2023, according to Kidney Research UK, a UK-based charitable organization that conducts research and advocacy efforts to improve understanding, prevention, and treatment of kidney diseases, an estimated 7.19 million people in the UK were affected by chronic kidney disease in 2023, representing more than 10% of the UK population and projected to increase to 7.61 million people by 2033. Therefore, the increasing prevalence of chronic kidney disease is driving the growth of the dialysis hyperphosphatemia therapeutics industry.

Key Players In The Global Dialysis Hyperphosphatemia Therapeutics Market

Major companies operating in the dialysis hyperphosphatemia therapeutics market are Akebia Therapeutics Inc., Alebund Pharmaceuticals (Jiangsu) Limited, Alkem Laboratories Ltd., Amgen Inc., Amneal Pharmaceuticals Inc., Ardelyx Inc., Aurobindo Pharma Limited, Biocon Limited, Cipla Limited, Vifor Pharma Management Ltd., Dr. Reddy’s Laboratories Ltd., Emcure Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Lupin Limited, OPKO Health Inc., R1 Therapeutics, Sanofi, Sanwa Kagaku Kenkyusho Co. Ltd., Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Unicycive Therapeutics Inc., Zydus Lifesciences Limited

Global Dialysis Hyperphosphatemia Therapeutics Market Trends and Insights

Major companies operating in the dialysis hyperphosphatemia therapeutics market are focusing on developing innovative therapies, such as phosphate absorption inhibitors to improve serum phosphorus control and reduce pill burden in dialysis patients. Phosphate absorption inhibitors are advanced therapies that reduce phosphate uptake in the intestine by blocking phosphate transport pathways rather than binding phosphate in the gastrointestinal tract such as conventional phosphate binders. For instance, in October 2023, Ardelyx Inc a US-based biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for XPHOZAH, the first phosphate absorption inhibitor indicated for adults with chronic kidney disease (CKD) on dialysis who have an inadequate response to phosphate binder therapy. XPHOZAH utilizes a differentiated mechanism of action that blocks paracellular phosphate absorption in the intestine and is administered as a single tablet twice daily, helping reduce serum phosphorus levels while lowering the daily pill burden compared to traditional phosphate binder treatments.

What Are Latest Mergers And Acquisitions In The Dialysis Hyperphosphatemia Therapeutics Market?

In March 2026, Alebund Pharmaceuticals (Jiangsu) Limited (Jiangsu) Limited, a China-based renal-focused biopharmaceutical company, partnered with R1 Therapeutics Inc. to advance the development of kidney disease therapies. With these agreements, Alebund Pharmaceuticals (Jiangsu) Limited aims to expand its renal therapeutics pipeline and strengthen strategic collaboration in kidney care innovation, while R1 Therapeutics seeks to accelerate clinical-stage development through funding support and partnerships with leading dialysis providers and global investors. R1 Therapeutics Inc. is a US-based clinical-stage biotechnology company focused on developing therapies for kidney diseases.

What Defines the Dialysis Hyperphosphatemia Therapeutics Market?

The dialysis hyperphosphatemia therapeutics market consists of sales of calcium-based phosphate binders, non-calcium phosphate binders, iron-based phosphate binders, vitamin D analog combinations, calcimimetic therapies, and oral tablets and capsules.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Dialysis Hyperphosphatemia Therapeutics Market Report 2026?

The dialysis hyperphosphatemia therapeutics market research report is one of a series of new reports from The Business Research Company that provides dialysis hyperphosphatemia therapeutics market statistics, including dialysis hyperphosphatemia therapeutics industry global market size, regional shares, competitors with a dialysis hyperphosphatemia therapeutics market share, detailed dialysis hyperphosphatemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the dialysis hyperphosphatemia therapeutics industry. This dialysis hyperphosphatemia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.